枸地氯雷他定与依匹斯汀治疗慢性荨麻疹随机对照研究

目的 探讨枸地氯雷他定和依匹斯汀治疗慢性荨麻疹的疗效和安全性。 方法 随机、双盲、双模拟和对照研究。试验组服枸地氯雷他定胶囊每日1次，每次8.8 mg，对照组依匹斯汀胶囊每日1次，每次10 mg，均连续服用28 d。于用药后随访，观察疗效和不良反应。 结果 入选病例157例，可评价疗效和安全性病例142例。经28 d治疗后，枸地氯雷他定组有效率81.16％、依匹斯汀组有效率78.08％，两组比较差异无统计学意义（P > 0.05）。枸地氯雷他定组和对照组药物相关性不良反应发生率分别为13.89％和12.16％，两组比较差异无统计学意义（P > 0.05）。 结论 枸地氯雷他定治疗慢性荨麻疹安全有效。

Desloratadine citrate disodium versus epinastine for the treatment of chronic urticaria: a randomized controlled trial

Yan Yi *, Liu Ruizhen, Xu Degang. *Department of Dermatology, Ganzhou Hospital of Dermatology, Ganzhou 341000, Jiangxi, China Corresponding author: Yan Yi, Email: yanyibest@tom.com 【Abstract】 Objective To evaluate the efficacy and safety of desloratadine citrate disodium versus epinastine for the treatment of chronic urticaria （CU）. Methods A randomized, double-blind, double-dummy controlled clinical trial was conducted. Patients with CU were divided into test group and control group to be treated by oral desloratadine citrate disodium （8.8 mg/d） and epinastine （10 mg/d） respectively once a day for 28 days. All the patients were followed up after starting treatment. Therapeutic effect was evaluated, and adverse reactions were observed. Results One hundred and fifty-seven patients were enrolled in this study, and 142 patients were valid for evaluation of efficacy and safety at the end of study. After treatment for 28 days, there was no significant difference between the test group and control group in response rate （81.16 % vs. 78.08 %, P > 0.05） or incidence rate of adverse reactions （13.89 % vs. 12.16 %, P > 0.05）. Conclusion Desloratadine citrate disodium is effective and safe for the treatment of CU.